Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$33.96
-1.5%		$23.58
$9.71
▼
$41.14
$3.78B-0.131.69 million shs1.56 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$152.32
+0.4%		$133.66
$77.58
▼
$156.92
$375.80B0.2110.82 million shs6.50 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$843.47
-1.0%		$729.93
$541.00
▼
$859.34
$86.84B0.19839,671 shs496,180 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+2.01%-6.98%+71.00%+141.02%+245.59%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.41%-0.89%+18.89%+26.29%+77.92%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+3.42%+4.57%+12.22%+35.52%+47.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$33.96
-1.5%		$23.58
$9.71
▼
$41.14
$3.78B-0.131.69 million shs1.56 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$152.32
+0.4%		$133.66
$77.58
▼
$156.92
$375.80B0.2110.82 million shs6.50 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$843.47
-1.0%		$729.93
$541.00
▼
$859.34
$86.84B0.19839,671 shs496,180 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+2.01%-6.98%+71.00%+141.02%+245.59%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+1.41%-0.89%+18.89%+26.29%+77.92%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+3.42%+4.57%+12.22%+35.52%+47.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.507.48% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$147.60-3.10% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.58
Moderate Buy$800.36-5.11% Downside

Current Analyst Ratings Breakdown

Latest AMLX, REGN, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$55.00 ➝ $57.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $170.00
8/21/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $160.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$142.00 ➝ $170.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $175.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$142.00 ➝ $150.00
8/20/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$116.00 ➝ $179.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$28.00 ➝ $52.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/A$2.15 per shareN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.78$11.61 per share13.12$17.02 per share8.95
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$15.53B5.59$42.97 per share19.63$308.01 per share2.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25121.8615.776.524.77%16.73%6.13%10/29/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4620.8516.691.6127.86%13.47%10.34%10/28/2026 (Estimated)

Latest AMLX, REGN, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.022.95%N/AN/A N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.24%+5.75%272.00%14 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.44%N/A9.29%N/A

Latest AMLX, REGN, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.42 million99.28 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells 400 Shares
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-regeneron-pharmaceuticals-nasdaq-regn-director-kathryn-guarini-sells-400-shares-2026-09-03/
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells 1,131 Shares of Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-regeneron-pharmaceuticals-nasdaq-regn-evp-sells-1131-shares-of-stock-2026-09-03/
Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $1,032,750.00 in Stock
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-regeneron-pharmaceuticals-nasdaq-regn-evp-sells-103275000-in-stock-2026-09-03/
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-alert-hagens-berman-alerts-regeneron-pharmaceuticals-inc-regn-investors-to-pending-securities-fraud-class-action-amid-disclosures-about-key-trials-protocol-and-ultimate-failure-302869289.html
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 3 at 10:33 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3356083/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-sbs-law.html
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt
September 3 at 10:07 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-investor-alert-regeneron-pharmaceuticals-inc-securities-class-action-notice---contact-suewallst-302868726.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
September 3 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines--regn-302868495.html
REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
September 2 at 6:36 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355577/32716/en/regn-12-day-deadline-alert-regeneron-pharmaceuticals-inc-investors-alerted-to-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit.html
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 2 at 4:35 PM  |  newsfilecorp.comN
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High - Here's Why
September 2 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-regeneron-pharmaceuticals-nasdaq-regn-reaches-new-12-month-high-heres-why-2026-09-02/
Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion: What Investors Should Watch
September 2 at 12:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/regenerons-cemiplimab-combo-trial-with-sns-101-reaches-completion-what-investors-should-watch?utm_source=marketbeat.com&utm_medium=referral
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
September 2 at 12:23 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/2026-complement-inhibitors-market-analysis-111700039.html
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
September 2 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355368/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026
September 2 at 10:11 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-deadline-alert-levi--korsinsky-reminds-regeneron-pharmaceuticals-regn-investors-of-securities-class-action-deadline-on-september-14-2026-302867382.html
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
September 2 at 9:02 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355211/0/en/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-regeneron-pharmaceuticals-inc-regn.html
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
September 2 at 6:51 AM  |  barchart.comhttps://www.barchart.com/story/news/4395012/regeneron-pharmaceuticals-stock-is-regn-outperforming-the-healthcare-sector
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
September 1 at 5:29 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354692/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines-regn.html
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors
September 1 at 3:53 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354557/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-regeneron-pharmaceuticals-inc-investors.html
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline
September 1 at 12:21 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-deadline-regeneron-pharmaceuticals-inc-regn-investors-with-substantial-losses-have-opportunity-to-lead-the-regeneron-class-action-lawsuit-before-september-14-2026-deadline-302866488.html
Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035
September 1 at 10:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/non-melanoma-skin-cancer-market-090300846.html
REGN UPCOMING DEADLINE: SueWallSt Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm
September 1 at 10:29 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354381/0/en/regn-upcoming-deadline-suewallst-alerts-regeneron-pharmaceuticals-inc-stockholders-of-securities-class-action-contact-the-firm.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$33.96 -0.53 (-1.54%)
As of 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$152.32 +0.68 (+0.45%)
As of 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$843.47 -8.56 (-1.00%)
As of 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas